AMLX — Amylyx Pharmaceuticals Inc · catalysts, narrative & risks

Overview

Amylyx Pharmaceuticals (NASDAQ: AMLX) is a Cambridge, Massachusetts biopharmaceutical company that is repositioning itself away from its ALS legacy (AMX0035/Relyvrio, withdrawn in North America in April 2024) toward a late-stage endocrine/metabolic company built around its lead asset avexitide for post-bariatric hypoglycemia (PBH) [1], [2], [22]. The stock has experienced extreme volatility over the past several months, and near the reference date (Oct 2, 2026) it was trading around $27.79, well off a 52-week high of ~$41.14, with a market capitalization of roughly $3.1 billion [20].

Recent Catalysts (July–October 2026)